Denise Yardley, MD
CDK4/6 inhibitors have recently taken the forefront of the landscape when it comes to hormone-positive breast cancer, experts say.
on Advanced Breast Cancer, Yardley, a senior investigator of breast cancer research at Sarah Cannon Research Institute, discussed the promise of CDK4/6 inhibitors in estrogen receptor (ER)–positive breast cancer, as well as the potential with immunotherapy agents.
OncLive: Your presentation is on ER-positive breast cancer. Can you give an overview of what you talked about?
My presentation looked at some of the changes in the management of hormone receptor (HR)–positive, HER2-negative breast cancer. I really embraced all phases of treatment, such as going to early adjuvant breast cancer treatment recommendations, and some of the recommendations with regard to extended adjuvant therapy.
... to read the full story